WAY-317538

WAY-317538
Legal status
Legal status	In general: legal;
Identifiers
	IUPAC name 5-Morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide;
CAS Number	874450-44-9 ;
PubChem CID	45484303; HCl: 45484302;
ChemSpider	24663034 ;
UNII	M92TU1EZ75;
ChEMBL	ChEMBL1084615 ; HCl: ChEMBL565540 ;
CompTox Dashboard (EPA)	DTXSID30670437 ;
Chemical and physical data
Formula	C20H25N3O2
Molar mass	339.439 g·mol−1
3D model (JSmol)	Interactive image; HCl: Interactive image;
	SMILES C3COCCN3CCCCC(=O)Nc1ccc(cc1)-c2cccnc2; ; HCl: C1COCCN1CCCCC(=O)NC2=CC=C(C=C2)C3=CN=CC=C3.Cl;
	InChI InChI=1S/C20H25N3O2/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24) ; Key:XCHIZTUBUXZESJ-UHFFFAOYSA-N ; ; HCl: InChI=1S/C20H25N3O2.ClH/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18;/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24);1H; Key:GBMDUJQQSGOIFW-UHFFFAOYSA-N;
	(what is this?) (verify)

WAY-317538 (SEN-12333) is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It was not the most potent compound in the series, but was selected for further development on the basis of its high selectivity over related receptors, ease of synthesis, and good in vivo properties including high oral bioavailability and good brain penetration.^[1] It has nootropic and neuroprotective effects in animal studies, and is being investigated as a potential treatment for neurodegenerative and neurocognitive conditions including Alzheimer's disease and schizophrenia.^[2]

References

^ Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, et al. (July 2009). "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist". Bioorganic & Medicinal Chemistry. 17 (14): 5247–58. doi:10.1016/j.bmc.2009.05.040. PMID 19515567.
^ Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, et al. (May 2009). "Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 459–68. doi:10.1124/jpet.108.150094. PMID 19223665. S2CID 6667145.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, et al. (July 2009). "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist". Bioorganic & Medicinal Chemistry. 17 (14): 5247–58. doi:10.1016/j.bmc.2009.05.040. PMID 19515567.

[2] Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, et al. (May 2009). "Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 459–68. doi:10.1124/jpet.108.150094. PMID 19223665. S2CID 6667145.

[1]

[2]

Legal status

Legal status	In general: legal
Identifiers
IUPAC name 5-Morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide
CAS Number	874450-44-9^N
PubChem CID	45484303 HCl: 45484302
ChemSpider	24663034^N
UNII	M92TU1EZ75
ChEMBL	ChEMBL1084615^N HCl: ChEMBL565540^N
CompTox Dashboard (EPA)	DTXSID30670437
Chemical and physical data
Formula	C₂₀H₂₅N₃O₂
Molar mass	339.439 g·mol⁻¹
3D model (JSmol)	Interactive image HCl: Interactive image
SMILES C3COCCN3CCCCC(=O)Nc1ccc(cc1)-c2cccnc2 HCl: C1COCCN1CCCCC(=O)NC2=CC=C(C=C2)C3=CN=CC=C3.Cl
InChI InChI=1S/C20H25N3O2/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24)^N Key:XCHIZTUBUXZESJ-UHFFFAOYSA-N^N HCl: InChI=1S/C20H25N3O2.ClH/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18;/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24);1H Key:GBMDUJQQSGOIFW-UHFFFAOYSA-N
^NY (what is this?) (verify)